Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 9/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593791 | 0.78 | CYP17A1 (0.63) | CYP17A1CYP1A2PRKCZCYP11B2CYP11B1 | |
| SCHEMBL2591802 | 0.76 | CYP17A1 (0.52) | CYP17A1CYP1A2PRKCZEGFRCYP11B2 | |
| SCHEMBL2592210 | 0.74 | CYP17A1 (0.42) | CYP17A1CYP1A2EGFRCYP11B2CYP11B1 | |
| SCHEMBL2594029 | 0.74 | CYP17A1 (0.47) | CYP17A1CYP1A2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL20873066 | 0.72 | PRKCZ (0.64) | CYP17A1CYP1A2PRKCZCYP11B2CYP11B1 | |
| SCHEMBL2593570 | 0.71 | CYP17A1 (0.61) | CYP17A1CYP1A2CYP3A4 | |
| SCHEMBL20873077 | 0.67 | CYP1A2 (0.57) | CYP17A1CYP1A2PRKCZKCNA5KCNH2 | |
| SCHEMBL16331136 | 0.67 | MKNK1 (0.54) | CYP17A1PRKCZCYP11B2CYP11B1LRRK2 | |
| SCHEMBL30359418 | 0.66 | PRKCZ (0.53) | CYP17A1CYP1A2PRKCZCYP11B2CYP11B1 | |
| SCHEMBL4562594 | 0.63 | CYP17A1 (1.00) | CYP17A1CYP1A2CYP11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2563792-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | Bristol-Myers Squibb Company (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | CYP2C19, CYP3A7, CYP2C18 | CYP17A1 54/4885CYP1A2 9/4885PRKCZ 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.